期刊文献+

沙利度胺联合盐酸托烷司琼对转移性乳腺癌GP方案化疗所致恶心呕吐的疗效观察 被引量:13

原文传递
导出
摘要 探讨沙利度胺联合盐酸托烷司琼对转移性乳腺癌使用高致吐性化疗药物所致的恶心呕吐的预防作用。方法将2011年1月至2013年7月收治的81例转移性乳腺癌患者随机分成实验组(41例)和对照组(40例)。均采用GP方案:吉西他滨1 000 mg/m2,第1、8天;顺铂75 mg/m2,第1天。对照组用盐酸托烷司琼注射液5 mg,化疗前30 min静脉推注。实验组在对照组的基础上加用沙利度胺片25 mg口服,2次/d,d1~d8。结果实验组和对照组的急性恶心的有效率分别为95.1%和95.0%,急性呕吐的有效率分别为80.5%和77.5%,两组差异均无统计学意义(P均〉0.05)。实验组和对照组化疗所致延迟性恶心的有效率分别为58.5%和22.5%,延迟性呕吐的有效率78.0%和52.5%,实验组均高于对照组(P均〈0.05)。实验组和对照组的不良反应可耐受,嗜睡、乏力、便秘、头痛和皮疹的发生率差异均无统计学意义(P均〉0.05)。结论沙利度胺联合盐酸托烷司琼治疗能有效预防高致吐性药物引起的延迟性恶心呕吐,不良反应轻微。
作者 左彩莹
出处 《中国临床研究》 CAS 2014年第12期1491-1493,共3页 Chinese Journal of Clinical Research
  • 相关文献

参考文献14

二级参考文献45

  • 1黄海辉,王东林,梁后杰,陈晓品,陈小勇.国产盐酸托烷司琼治疗顺铂化疗所致恶心、呕吐的疗效与安全性评价[J].中国药房,2005,16(17):1318-1320. 被引量:17
  • 2要洁,冯奉仪,林晨,张雪燕,付明,梁萧,杨莹.吉西他滨耐药胰腺癌细胞系的耐药机制[J].中华肿瘤杂志,2005,27(12):721-726. 被引量:8
  • 3吴东平,吕杰青,陶锋,王建芳,王松祥.FOLFOX4方案治疗晚期结直肠癌的临床观察[J].肿瘤研究与临床,2006,18(4):255-257. 被引量:6
  • 4Hsueh-Erh Chiou,Tsang-En Wang,Ying-Yue Wang,Hui-Wen Liu.Efficacy and safety of thalidomide in patients with hepatocellular carcinoma[J].World Journal of Gastroenterology,2006,12(43):6955-6960. 被引量:21
  • 5Gordon JN, Trebble TM, Ellis RD, et al. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial [ J ]. Gut, 2005,54(4) :540 -545.
  • 6Kenyon BM. Effects of thalidomide and related metabolites in a mouse comeal of nevoscularization [ J ]. Exp Eye Res, 1997,64:971.
  • 7Or R. Thalidomide reduces vascular density in granulationtissue of subcutaneously implantsd polyvingyl alcohol pongees in guinea pigs[ J ]. Exp Hematol, 1998,26:217.
  • 8Hsu C, huang CS, Chao T Y , et al. Phase Ⅱ trial combining paclitaxel with 24 - hour infusion cisplatin for chemotherapy- nave patients with locally advanced or metastatic breast carcinoma [ J ]. Cancer ,2002, 95(10) :2044 -2050.
  • 9Minami M,Endo T.Hirataji M,et al.Pharmacological aspects of anticancer drug-induced emasis with emphasis on serotonin release and vagal never activity[J].Pharmacol Ther,2003,99:149-165
  • 10Blumen H.The interaction between PPI and orthr drugs[J].Drug Safety,2006,29(9):769-771.

共引文献67

同被引文献115

  • 1万崇华,陈明清,张灿珍,汤学良,孟琼,张晓磬.癌症患者生命质量测定量表EORTC QLQ-C30中文版评介[J].实用肿瘤杂志,2005,20(4):353-355. 被引量:1265
  • 2常青,毛小玲,潘素滢.中西医结合防治顺铂所致急性胃肠反应的临床研究[J].中华中医药学刊,2007,25(5):990-991. 被引量:5
  • 3KElIebaek E, Hetedt J. Optimizing antiemetic therapy in multiple - day and muhiple cycles of chemotherapy[ J]. Curt Opin Support Palliat Care. ,2008,2 ( l ) :28 - 34.
  • 4Molassiotis A, Saunders MP, Valle J, et al. A prospective obser- vational study of chemotherapy - related nausea and vomiting in routine practice in a UK cancer centre [ J]. Support Care Canc,2008,16(2) :201 -208.
  • 5Aapro MS, Schmoll H J, Jahn F, et al. Review of the efficacy of aprepitant for the prevention of chemotherapy - induced nausea and vomiting in a range of tumor types[J]. Cancer treatment reviews, 2013,39(1) :113 - 117.
  • 6Mertens WC, Higby DJ, Brown D, et al. Improving the care of patients with regard to chemotherapy - induced nausea and emesis : the effect of feedback to clinicians on adherence to antiemetic pre- scribing guidelines[ J]. J Clin Oneol, 2003 ;21 (7) : 1373 - 1378.
  • 7Caracuel F, Bauos U, Herrera MD, et al. Influence of pharma- ceutical care on the delayed ernesis associated with chemotherapy [J]. Int J Clin Pharna,2014, 36(2) :287 -290.
  • 8Liekweg A, Westfeld M, Braun M, et al. Pharmaceutical care for patients with breast and ovarian cancer[ J]. Support Care Cancer, 2012,20 ( 11 ) :2669 - 2677.
  • 9Wong SF, Bounthavong M, Nguyen C, et al. Implementation and preliminary outcomes of a comprehensive oral chemotherapy man- agement clinic[J]. Am J Health Syst Pharm. ,2014,71 (11) :960 - 965.
  • 10Oz ES, Aydemir E,Fiskin K. Dmso exhibits similar cyto- toxicity effects to thalidomide in mouse breast cancer cells [J]. Oncol Letters, 2012,3(4) : 927-929.

引证文献13

二级引证文献104

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部